AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal

AstraZeneca boosts China presence with FibroGen’s anemia drug in $160 million deal

(Reuters) -AstraZeneca will buy longtime partner FibroGen’s China unit for about $160 million to gain rights to its anemia drug in the country, further boosting its presence in the world’s second-biggest economy. The deal comes at a time when the Anglo-Swedish pharma company is facing a string of investigations in the country, AstraZeneca’s biggest international…

Read More
China’s ports adopt DeepSeek AI model to streamline operations, protect data

China’s ports adopt DeepSeek AI model to streamline operations, protect data

China’s home-grown technological innovations – like the DeepSeek large language model that has taken the artificial intelligence (AI) industry by storm – are enabling the world’s second-largest economy to empower industries and critical infrastructure to carry out their core functions with fewer concerns over data security. Just over a month since the January launch of…

Read More